005500 — Samjin Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩226bn
- KR₩331bn
- KR₩292bn
- 77
- 83
- 41
- 81
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 37,286 | 24,489 | 11,711 | 4,663 | 4,006 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 53,334 | 51,429 | 57,684 | 59,883 | 61,455 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 150,110 | 146,860 | 139,872 | 134,268 | 146,180 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 75,260 | 102,526 | 168,901 | 198,068 | 191,640 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 244,151 | 269,033 | 332,496 | 406,557 | 419,901 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30,707 | 33,935 | 49,514 | 81,652 | 144,550 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 46,677 | 55,577 | 98,328 | 131,213 | 154,536 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 197,474 | 213,456 | 234,168 | 275,344 | 265,365 |
Total Liabilities & Shareholders' Equity | 244,151 | 269,033 | 332,496 | 406,557 | 419,901 |
Total Common Shares Outstanding |